Literature DB >> 1913546

A tentative tumor-node-metastasis classification of thymoma.

Y Yamakawa1, A Masaoka, T Hashimoto, H Niwa, T Mizuno, Y Fujii, K Nakahara.   

Abstract

To establish a tumor-node-metastasis (TNM) classification of thymoma, 207 thymoma patients seen at the First Department of Surgery, Osaka University, and the Second Department of Surgery, Nagoya City University, were evaluated. Lymphogenous and hematogenous metastases of thymoma were infrequent, but their frequency increased with the duration of the course. Lymphogenous metastasis was observed in few cases, but it was considered to progress from anterior mediastinal lymph nodes to intrathoracic and then to extrathoracic lymph nodes. No particular characteristics were observed in hematogenous metastasis. On the basis of these observations, a TNM classification of thymoma was established and applied it to 207 thymoma cases, but it had little advantage over conventional clinical staging. High percentages of thymic carcinomas and thymic carcinoids were in Stage IVB, and the TNM classification of these tumors was considered to be more useful.

Entities:  

Mesh:

Year:  1991        PMID: 1913546     DOI: 10.1002/1097-0142(19911101)68:9<1984::aid-cncr2820680923>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 years.

Authors:  Nicola M Neary; Ariel Lopez-Chavez; Brent S Abel; Alison M Boyce; Nicholas Schaub; King Kwong; Constantine A Stratakis; Cesar A Moran; Giuseppe Giaccone; Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2012-04-16       Impact factor: 5.958

2.  Unusual late presentation of metastatic extrathoracic thymoma to gastrohepatic lymph node treated by surgical resection.

Authors:  Andrea Billè; Sandeep Sachidananda; Andre L Moreira; Nabil P Rizk
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-11-30

Review 3.  Thymic carcinoma successfully resected with superior vena cava after chemoradiotherapy.

Authors:  Y Shintani; M Ohta; K Hazama; S Miyoshi; K Kagisaki; H Matsuda
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-12

Review 4.  Thymomas. Current experience and future directions in therapy.

Authors:  P J Loehrer
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

5.  Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study.

Authors:  Kazunari Tateishi; Ryo Ko; Takehito Shukuya; Yusuke Okuma; Satoshi Watanabe; Shoichi Kuyama; Kyoko Murase; Yoko Tsukita; Hironori Ashinuma; Taku Nakagawa; Kazutsugu Uematsu; Mika Nakao; Yoshiaki Mori; Kyoichi Kaira; Atsuto Mouri; Takao Miyabayashi; Hiroyuki Sakashita; Yoko Matsumoto; Tomoyuki Tanigawa; Tomonobu Koizumi; Satoshi Morita; Kunihiko Kobayashi; Toshihiro Nukiwa; Kazuhisa Takahashi
Journal:  Oncologist       Date:  2019-11-26

6.  Malignant thymoma with direct invasion into the peritoneal cavity: report of a case.

Authors:  T Fujikawa; Y Nakamura; S Matsusue; H Takeda; Y Kori; M Sonobe
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

7.  Thymoma: does tumor size matter?

Authors:  Arya Amini; Chad G Rusthoven
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

8.  Cytoplasm estrogen receptor β5 as an improved prognostic factor in thymoma and thymic carcinoma progression.

Authors:  Sheng-Ying Li; Yu-Xia Wang; Lei Wang; Zhi-Bing Qian; Ming-Li Ji
Journal:  Oncol Lett       Date:  2015-07-30       Impact factor: 2.967

9.  Computed tomography and thymoma: distinctive findings in invasive and noninvasive thymoma and predictive features of recurrence.

Authors:  A M Priola; S M Priola; M Di Franco; A Cataldi; S Durando; C Fava
Journal:  Radiol Med       Date:  2009-12-16       Impact factor: 3.469

10.  Thymic neoplasm: a rare disease with a complex clinical presentation.

Authors:  Omar M Rashid; Anthony D Cassano; Kazuaki Takabe
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.